Asunto(s)
COVID-19 , SARS-CoV-2 , Enfermedad Crítica , Humanos , Evasión Inmune , Factores de RiesgoRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Anciano , Hipersensibilidad al Huevo/diagnóstico , Hipersensibilidad a los Alimentos/diagnóstico , Hipersensibilidad Inmediata/diagnósticoAsunto(s)
Hiponatremia/etiología , Síndrome de Secreción Inadecuada de ADH/diagnóstico , Lupus Eritematoso Sistémico/complicaciones , Ciclofosfamida/uso terapéutico , Demencia/etiología , Femenino , Humanos , Síndrome de Secreción Inadecuada de ADH/complicaciones , Síndrome de Secreción Inadecuada de ADH/tratamiento farmacológico , Lupus Eritematoso Sistémico/metabolismo , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Sodio/sangre , Vasculitis/etiologíaRESUMEN
We carried out a double-blind clinical trial of immunotherapy on 35 patients sensitized to the storage mite Lepidoglyphus destructor (Ld). Before and after 12 months of specific hyposensitization (Abelló Lab., Spain) we performed in vivo (skin tests with Ld, methacholine and challenge tests), and in vitro tests (specific IgE, IgG, IgG1 and IgG4 to Ld and specific IgE, IgG, IgG1 and IgG4 to their major allergen Lep dI). We also monitored the efficacy and safety of the immunotherapy with clinical and analytical controls (symptoms and medication score, detection of immune complexes). After therapy we found a significant decrease in specific skin reactivity, dose of positive challenge tests, and hyperresponsiveness to methacholine. Sputum eosinophilia decreased. Specific IgE to Ld was increased and we also observed an increase in specific IgG1 and IgG4 to Ld and Lep DI. The placebo group showed no changes in these variables. There were no severe secondary reactions after treatment with the extract. Patients-self-evaluation was favourable and their labour absence decreased. No development of circulating immune complexes was associated with this immunotherapy.
Asunto(s)
Alérgenos , Conjuntivitis Alérgica/terapia , Inmunoterapia , Ácaros , Rinitis Alérgica Perenne/terapia , Adolescente , Adulto , Animales , Niño , Conjuntivitis Alérgica/inmunología , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Rinitis Alérgica Perenne/inmunologíaRESUMEN
Although contact dermatitis is cited among the side effects of topical application of nitroglycerin, in the majority of cases the reactions are caused by an irritant mechanism, and it is only rarely due to an allergic mechanism. We present two patients with allergic contact dermatitis and review the existing bibliography.
Asunto(s)
Dermatitis Alérgica por Contacto/etiología , Nitroglicerina/efectos adversos , Administración Tópica , Anciano , Angina de Pecho/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Nitroglicerina/administración & dosificación , Nitroglicerina/uso terapéuticoRESUMEN
A 72-year-old woman presented with generalized urticaria after receiving an injection of aztreonam. After successive in vitro and in vivo studies, allergy to aztreonam with a good tolerance of the other beta-lactams was diagnosed.
Asunto(s)
Aztreonam/efectos adversos , Erupciones por Medicamentos/etiología , Urticaria/inducido químicamente , Anciano , Antibacterianos/efectos adversos , Antibacterianos/química , Antibacterianos/inmunología , Aztreonam/química , Aztreonam/inmunología , Reacciones Cruzadas , Erupciones por Medicamentos/diagnóstico , Femenino , Humanos , Pruebas Cutáneas , Relación Estructura-ActividadRESUMEN
We carried out a double-blind clinical trial in 30 patients who were sensitized to Bermuda grass pollen. Before and after immunotherapy we performed in vivo tests (skin tests and standardized tests of specific and nonspecific bronchial hyperreactivity), in vitro tests (histamine release), and specific IgE and IgG antibodies to BGP. We found a significant decrease (P less than .001) in specific bronchial hyperreactivity and skin sensitivity to BGP in the group of patients treated with immunotherapy, a decrease in the delayed responses (P less than .05) in histamine release (P less than .01), and an increase (P less than .001) in specific IgE and IgG antibodies to BGP. The placebo group showed no changes in these parameters.